127 related articles for article (PubMed ID: 37707874)
1. Double trouble: IRAK1/4 inhibitors in AML/MDS.
Uckelmann HJ; Klusmann JH
Blood; 2023 Sep; 142(11):945-946. PubMed ID: 37707874
[No Abstract] [Full Text] [Related]
2. Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML.
Bennett J; Ishikawa C; Agarwal P; Yeung J; Sampson A; Uible E; Vick E; Bolanos LC; Hueneman K; Wunderlich M; Kolt A; Choi K; Volk A; Greis KD; Rosenbaum J; Hoyt SB; Thomas CJ; Starczynowski DT
Blood; 2023 Sep; 142(11):989-1007. PubMed ID: 37172199
[TBL] [Abstract][Full Text] [Related]
3. IRAK1: oncotarget in MDS and AML.
Beverly LJ; Starczynowski DT
Oncotarget; 2014 Apr; 5(7):1699-700. PubMed ID: 24880611
[No Abstract] [Full Text] [Related]
4. Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes.
Hosseini MM; Kurtz SE; Abdelhamed S; Mahmood S; Davare MA; Kaempf A; Elferich J; McDermott JE; Liu T; Payne SH; Shinde U; Rodland KD; Mori M; Druker BJ; Singer JW; Agarwal A
Leukemia; 2018 Nov; 32(11):2374-2387. PubMed ID: 29743719
[TBL] [Abstract][Full Text] [Related]
5. Identification of optineurin as an interleukin-1 receptor-associated kinase 1-binding protein and its role in regulation of MyD88-dependent signaling.
Tanishima M; Takashima S; Honda A; Yasuda D; Tanikawa T; Ishii S; MaruYama T
J Biol Chem; 2017 Oct; 292(42):17250-17257. PubMed ID: 28882891
[TBL] [Abstract][Full Text] [Related]
6. Divergence of apoptosis-inducing and preventing signals in bacteria-faced macrophages through myeloid differentiation factor 88 and IL-1 receptor-associated kinase members.
Ruckdeschel K; Mannel O; Schröttner P
J Immunol; 2002 May; 168(9):4601-11. PubMed ID: 11971008
[TBL] [Abstract][Full Text] [Related]
7. A novel splice variant of interleukin-1 receptor (IL-1R)-associated kinase 1 plays a negative regulatory role in Toll/IL-1R-induced inflammatory signaling.
Rao N; Nguyen S; Ngo K; Fung-Leung WP
Mol Cell Biol; 2005 Aug; 25(15):6521-32. PubMed ID: 16024789
[TBL] [Abstract][Full Text] [Related]
8. Overcoming adaptive therapy resistance in AML by targeting immune response pathways.
Melgar K; Walker MM; Jones LM; Bolanos LC; Hueneman K; Wunderlich M; Jiang JK; Wilson KM; Zhang X; Sutter P; Wang A; Xu X; Choi K; Tawa G; Lorimer D; Abendroth J; O'Brien E; Hoyt SB; Berman E; Famulare CA; Mulloy JC; Levine RL; Perentesis JP; Thomas CJ; Starczynowski DT
Sci Transl Med; 2019 Sep; 11(508):. PubMed ID: 31484791
[TBL] [Abstract][Full Text] [Related]
9. Genetics of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Andersen MK; Andersen MT; Christiansen DH
Leukemia; 2008 Feb; 22(2):240-8. PubMed ID: 18200041
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of interleukin-1beta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88.
Chen BC; Wu WT; Ho FM; Lin WW
J Biol Chem; 2002 Jul; 277(27):24169-79. PubMed ID: 11976320
[TBL] [Abstract][Full Text] [Related]
11. IRAK1 and IRAK4 promote phosphorylation, ubiquitination, and degradation of MyD88 adaptor-like (Mal).
Dunne A; Carpenter S; Brikos C; Gray P; Strelow A; Wesche H; Morrice N; O'Neill LA
J Biol Chem; 2010 Jun; 285(24):18276-82. PubMed ID: 20400509
[TBL] [Abstract][Full Text] [Related]
12. A synthetic cell-penetrating peptide derived from nuclear localization signal of EPS8 exerts anticancer activity against acute myeloid leukemia.
Chen Y; Xie X; Wu A; Wang L; Hu Y; Zhang H; Li Y
J Exp Clin Cancer Res; 2018 Jan; 37(1):12. PubMed ID: 29357910
[TBL] [Abstract][Full Text] [Related]
13. Acute myeloid leukemia and myelodysplastic syndrome associated with a combination of immune checkpoint inhibitor and platinum-based chemotherapy.
Nakatsuru K; Tsubouchi K; Hirahata M; Nakashima T; Takahata Y; Okamatsu Y; Shiraishi Y; Okamoto I; Harada T
Thorac Cancer; 2023 Aug; 14(22):2225-2228. PubMed ID: 37337950
[TBL] [Abstract][Full Text] [Related]
14. FADD negatively regulates lipopolysaccharide signaling by impairing interleukin-1 receptor-associated kinase 1-MyD88 interaction.
Zhande R; Dauphinee SM; Thomas JA; Yamamoto M; Akira S; Karsan A
Mol Cell Biol; 2007 Nov; 27(21):7394-404. PubMed ID: 17785432
[TBL] [Abstract][Full Text] [Related]
15. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
[TBL] [Abstract][Full Text] [Related]
16. Kaposi's sarcoma-associated herpesvirus microRNAs target IRAK1 and MYD88, two components of the toll-like receptor/interleukin-1R signaling cascade, to reduce inflammatory-cytokine expression.
Abend JR; Ramalingam D; Kieffer-Kwon P; Uldrick TS; Yarchoan R; Ziegelbauer JM
J Virol; 2012 Nov; 86(21):11663-74. PubMed ID: 22896623
[TBL] [Abstract][Full Text] [Related]
17. Ras participates in CpG oligodeoxynucleotide signaling through association with toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages.
Xu H; An H; Yu Y; Zhang M; Qi R; Cao X
J Biol Chem; 2003 Sep; 278(38):36334-40. PubMed ID: 12867418
[TBL] [Abstract][Full Text] [Related]
18. A rock in the toll road: IRAK4 inhibition of TLR4-MyD88 signaling as potential treatment for addiction.
Gaulden AD; McReynolds JR
Brain Behav Immun; 2022 Aug; 104():74-75. PubMed ID: 35618228
[No Abstract] [Full Text] [Related]
19. Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms.
Greco M; D'Alò F; Scardocci A; Criscuolo M; Fabiani E; Guidi F; Di Ruscio A; Migliara G; Pagano L; Fianchi L; Chiusolo P; Hohaus S; Leone G; Voso MT
Blood Cells Mol Dis; 2010 Oct; 45(3):181-5. PubMed ID: 20655775
[TBL] [Abstract][Full Text] [Related]
20. Focal Adhesion Kinase as a Potential Target in AML and MDS.
Carter BZ; Mak PY; Wang X; Yang H; Garcia-Manero G; Mak DH; Mu H; Ruvolo VR; Qiu Y; Coombes K; Zhang N; Ragon B; Weaver DT; Pachter JA; Kornblau S; Andreeff M
Mol Cancer Ther; 2017 Jun; 16(6):1133-1144. PubMed ID: 28270436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
